Sign In
Buy GPCR
$48.04
-1.43 (-2.89%)
At Close: Jul 31, 2026
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
08:30am, Friday, 08'th Mar 2024
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space
03:40pm, Wednesday, 17'th Jan 2024
Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.
IPO watch 2024: Which new stocks will hit the market?
07:03am, Monday, 08'th Jan 2024
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
07:45am, Monday, 25'th Dec 2023
Structure Therapeutics stock declined sharply due to some data it published. The data show that its flagship drug candidate appears to be safe and effective.
7 Small-Cap Stocks That Wall Street Loves for Good Reason
04:21pm, Friday, 22'nd Dec 2023
As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
11:17am, Wednesday, 20'th Dec 2023
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
Structure Therapeutics shares sink after obesity drug trial results disappoint
01:24pm, Monday, 18'th Dec 2023
Structure Therapeutics shares plummeted more than 30% after clinical data for its investigational obesity drug failed to meet expectations. The company's pill GSBR-1290 is part of a class of weigh
Structure Therapeutics reports promising results for weight-loss pill
11:56am, Monday, 18'th Dec 2023
Structure Therapeutics Inc (NASDAQ: GPCR) says its experimental weight-loss pill showed promising results in a mid-stage trial. Its shares are still down more than 40% at writing.
New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.
11:29am, Monday, 18'th Dec 2023
Biotech Structure saw shares dive after the firm disclosed disappointing data for an experimental obesity pill.
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader
09:22am, Monday, 18'th Dec 2023
Structure's potential rival to Lilly in weight-loss drugs missed expectations on Monday, and GPCR stock took an absolute beating.
Structure Therapeutics stock plunges on new GLP-1 drug data
08:04am, Monday, 18'th Dec 2023
Structure Therapeutics Inc. American depositary receipts GPCR, +0.97% dropped 40% premarket on Monday after the company released new data from a study of GSBR-1290, its investigational diabetes and ob
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% st
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
12:26pm, Monday, 11'th Dec 2023
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
02:28pm, Wednesday, 29'th Nov 2023
Some of the hottest opportunities can be found in biotech stocks. Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2 Biotech Stocks That Could Soar in December
04:44pm, Sunday, 26'th Nov 2023
Biotech stocks with major catalysts can be powerful capital appreciation vehicles. Bluebird Bio and Structure Therapeutics both have significant events scheduled for next month.
